In a nutshell This study investigated the use of bortezomib (BTZ; Velcade) maintenance after allogeneic hematopoietic cell transplant (alloHCT) for improving relapse and chronic graft versus host disease (cGVHD) in patients with multiple myeloma (MM) that are young or high-risk. The data showed that BTZ maintenance is effective and safe in...
Read More
In a nutshell This study evaluated the health-related quality of life of patients with multiple myeloma (MM) after treatment with VTd (bortezomib, thalidomide, and dexamethasone) with or without daratumumab (D; Darzalex). The study found that all patients that received treatment had an improved quality of life, while...
Read MoreIn a nutshell This study examined the long-term survival of patients who received stem cell transplants (SCT) and compared them to the general population. The authors found that patients who received SCTs had almost the same chance of survival as the general population and identified factors that alter this chance. Some background Treatments such as...
Read MoreIn a nutshell This study examined the long-term survival of patients who received stem cell transplants (SCT) and compared them to the general population. The authors found that patients who received SCTs had almost the same chance of survival as the general population and identified factors that alter this chance. Some background Treatments such as...
Read MoreIn a nutshell This study investigated the effects of stem cell transplant and anti-cancer drug treatment for Multiple Myeloma. Stem cell transplant appeared to increase survival in patients with Multiple Myeloma. Some background Multiple myeloma (MM) is a type of cancer in which red blood cells over produce antibodies. Stem cell transplant is a common...
Read More
In a nutshell This study investigated the long-term outcomes of patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM) who received plerixafor (Mozobil) or placebo combined with G-CSF (granulocyte colony stimulating factor) before a stem cell transplant (SCT). This study concluded that adding plerixafor to G-CSF did not negatively...
Read More
In a nutshell This study investigated the long-term outcomes of patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM) who received plerixafor (Mozobil) or placebo combined with G-CSF (granulocyte colony stimulating factor) before a stem cell transplant (SCT). This study concluded that adding plerixafor to G-CSF did not negatively...
Read More
In a nutshell This study investigated the long-term outcomes of MCL (mantle cell lymphoma) patients who received RIST (reduced-intensity allogenic stem cell transplant) therapy. The authors concluded that RIST may be curative in MCL patients, even in those who relapsed after autoSCT (autologous stem cell transplant). Some background Mantle cell...
Read More
In a nutshell This study looked at the effect of autologous stem cell transplantation (auto-SCT) on patients with follicular lymphoma who have disease progression within 2 years of initial chemotherapy. The study found that patients who receive early auto-SCT have better survival rates than patients who do not receive auto-SCT. Some background...
Read MoreIn a nutshell This study looked at the effect of radiotherapy after autologous stem cell transplantation for patients with relapsed or difficult to treat diffuse large B-cell lymphoma. The study concluded that patients had better tumor control when treated with involved-field radiotherapy after autologous stem cell transplantation. Some...
Read More
In a nutshell This study looked at the effectiveness of autologous stem cell transplantation after their first remission for patients with high-risk diffuse large B-cell lymphoma. The study concluded that patients who received autologous stem cell transplantation had better outcomes than those who did not. Some background Diffuse large B-cell...
Read More
In a nutshell This study compared the effectiveness of autologous stem cell transplantation in patients with mantle cell lymphoma who either did or did not achieve a complete response after first line treatment. The study concluded that autologous stem cell transplantation is most useful for patients who have already achieved a complete...
Read More
